Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers (VERMEER)

NewAmsterdam Pharma

Status and phase: Begins enrollment in 2 months; Phase 2

Conditions: Antioxidant Absorption

Treatments: Drug: Obicetrapib 10mg; Drug: Placebo

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT06982508

TA-8995-207

Details and patient eligibility

About

The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are:

Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants.

Participants will:

Take Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Visual acuity > 20/60 in both eyes with or without corrective lenses

Exclusion criteria

• Type 2 diabetes
• Active liver disease
• Any clinically significant macular pathology

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 2 patient groups, including a placebo group

Obicetrapib 10mg

Experimental group

Treatment:

Drug: Obicetrapib 10mg

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo